DBV Technologies reported positive top‑line results from its pivotal Phase III Vitesse trial of the Viaskin peanut patch in children aged 4–7. The trial met its primary endpoint: 46.6% of treated children met the response criteria versus 14.8% on placebo, an absolute difference of 31.8 percentage points. DBV said it will submit a BLA to the FDA in the first half of next year and expects priority review possibilities. The Vitesse program enrolled more than 650 children and represents DBV’s strategy to deliver peanut antigen transdermally to induce desensitization. The company has previously faced FDA setbacks and manufacturing questions; regulators earlier requested adherence and additional efficacy data. Safety findings were dominated by expected skin reactions, with two treatment‑related anaphylaxis events reported but both patients continuing therapy. The readout reopens a path for a non‑injectable immunotherapy option for pediatric food allergy.